Prostate tumor specific peptide-peptoid hybrid prodrugs

Bioorg Med Chem Lett. 2015 Jul 15;25(14):2849-52. doi: 10.1016/j.bmcl.2015.04.092. Epub 2015 May 6.

Abstract

Inspired by naturally occurring host defense peptides, cationic amphipathic peptoids provide a promising scaffold for anti-cancer therapeutics. Herein, we report a library of peptide-peptoid hybrid prodrugs that can be selectively activated by prostate cancer cells. We have identified several compounds demonstrating potent anti-cancer activity with good to moderate selectivity. We believe that these prodrugs can provide a useful design principle for next generation peptide-peptoid hybrid prodrugs.

Keywords: Anti-cancer; Antimicrobial peptides; Peptidomimetics; Peptoids; Prodrug; Prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Humans
  • Male
  • Peptides / chemistry*
  • Peptidomimetics
  • Peptoids / chemistry*
  • Prodrugs / chemical synthesis
  • Prodrugs / chemistry*
  • Prodrugs / pharmacology
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Peptides
  • Peptidomimetics
  • Peptoids
  • Prodrugs